Skye Bioscience Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2012
Net Income	-37.64	-19.48	-8.52	-6.56	1.05	-19.19	-4.14	-3.5	-4.84	-2.73	Upgrade
Depreciation & Amortization	0.12	0.11	0.03	0	0	0	0.01	0.01	0.01	0	Upgrade
Share-Based Compensation	0.99	0.63	0.87	0.3	0.68	0.67	0.8	0.71	0.41	0.01	Upgrade
Other Operating Activities	22.58	5.99	1.14	0.2	-7.76	14.57	-1.04	-1.1	0.69	0.97	Upgrade
Operating Cash Flow	-13.95	-12.74	-6.47	-6.05	-6.03	-3.94	-3.33	-3.55	-3.73	-1.76	Upgrade
Capital Expenditures	-0.01	-0.03	-0.09	-0.01	0	-0	-0.02	-0.01	-0	-0.02	Upgrade
Acquisitions	6.61	5.24	0	0	0	0	0	0	0	0	Upgrade
Investing Cash Flow	6.6	5.21	-0.09	-0.01	0	-0	-0.02	-0.01	-0	-0.02	Upgrade
Share Issuance / Repurchase	11.73	0	13.07	6.13	6	3.19	0	0	0.72	1.99	Upgrade
Debt Issued / Paid	4.71	-0.21	0	0.57	0.01	2.35	0.5	0	0	0	Upgrade
Other Financing Activities	-0.01	0	0.01	-	-	-	3.01	0.41	6.02	-	Upgrade
Financing Cash Flow	16.44	-0.21	13.08	6.7	6	5.54	3.51	0.41	6.74	1.99	Upgrade
Net Cash Flow	9.09	-7.74	6.51	0.64	-0.02	1.59	0.16	-3.16	3.01	0.21	Upgrade
Free Cash Flow	-13.96	-12.77	-6.57	-6.06	-6.03	-3.95	-3.35	-3.56	-3.73	-1.78	Upgrade
Free Cash Flow Per Share	-1.99	-5.75	-4.04	-6.57	-11.15	-8.14	-30.02	-47.03	-55.05	-43.20	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).